INTRODUCTION {#S6}
============

Iron deficiency, alone or with resulting anemia, continues to be the most prevalent micronutrient deficiency in the world ([@R1],[@R2]). It is associated with poor cognitive function, decreased work performance, and an increase in the frequency of low birth weight, prematurity, and perinatal mortality. Adverse effects of zinc supplementation on iron status have been demonstrated in a number of animal and adult human studies, including lowered iron absorption, hemoglobin and serum ferritin concentrations ([@R3]--[@R6]). The Dietary Reference Intakes (DRI) lists disruptions in iron metabolism as one of the early signs of excessive zinc intake ([@R7]). The impact of zinc supplementation on iron status in children is less clear, as the results of clinical trials examining interactions between iron and zinc have varied widely. Hemoglobin and ferritin improve more when iron is given alone than when paired with zinc supplementation ([@R8],[@R9]). However, two meta-analyses have concluded that zinc supplementation has not been shown to decrease hemoglobin or ferritin concentrations in children ([@R10],[@R11]). Of note, few trials have included infants age six months or younger.

In contrast to the potential negative effects of zinc on iron status, we and others have shown that multivitamin supplementation has beneficial effects on hemoglobin in young children in resource-limited settings. Two large trials among young infants, one in multiple countries ([@R12]) and another in a malaria endemic region ([@R13]), found that supplementation with multiple micronutrients was more effective than iron alone in the prevention and treatment of anemia. In secondary analyses of a randomized trial in infants born to HIV-infected women in Tanzania, we found that daily multivitamin supplementation (vitamin B complex, C and E) from ages 6 weeks to 25.5 months led to higher hemoglobin concentrations and lower risk for anemia, compared with placebo ([@R14]).

We conducted a trial comparing the effects of daily supplementation with zinc, multivitamin, combination zinc and multivitamin, or placebo from ages 6 weeks to 19.5 months on infectious morbidity in infants born to HIV-negative mothers in Dar es Salaam, Tanzania ([@R15]). In secondary analyses of data from this study, we aimed to examine effects of zinc and multivitamin supplementation on infant iron and hematologic status.

METHODS {#S7}
=======

Study design and participants {#S8}
-----------------------------

This study is a secondary analysis of a randomized, double-blind, 2 × 2 factorial design trial ([@R15]). Consenting HIV-negative mothers were enrolled shortly after or before delivery, and their infants were randomized between 5--7 weeks of age. The sample size was chosen based on power calculations for the primary endpoints of the parent study (\# lower respiratory illness episodes/year). Exclusion criteria were: multiple births, congenital anomalies, and other conditions that would interfere with the study procedures.

All study procedures were approved by the Harvard T.H. Chan School of Public Health Human Subjects Committee, the Muhimbili University of Health and Allied Science Senate Research and Publications Committee, the Tanzanian National Institute of Medical Research, and the Tanzanian Food and Drugs Authority. All mothers provided written informed consent.

Randomization and masking {#S9}
-------------------------

Infants were randomly assigned to receive one of four daily oral regimens for 18 months from the date of randomization: 1) Zinc (Zn); 2) Multivitamins (MV); 3) Zn+MV; 4) Placebo. A randomization list (1 to 2400) was created by a biostatistician, using blocks of 20, with stratification by study clinic. Supplements were manufactured by Nutriset (Malaunay, France), prepared as an orange-flavoured powder in opaque gelatinous capsules. In field testing, all four regimens were found to be indistinguishable between groups in taste, smell and appearance. All study personnel and participants remained blinded to treatment assignment for the duration of the study.

Procedures {#S10}
----------

Infants received one capsule per day from randomization through 6 months of age, and two capsules/day from 7 months of age to end of follow-up. The capsule provided to infants in the Zn group contained 5 mg zinc sulfate (ZnSO~4~). The capsule provided to the MV group contained 60 mg vitamin C, 8 mg vitamin E, 0.5 mg vitamin B-1, 0.6 mg vitamin B-2, 4 mg niacin, 0.6 mg vitamin B-6, 130 μg folate, and 1 μg vitamin B-12. The MV+Zn group received the micronutrients listed in both the MV and Zn groups in a single capsule. Supplement dosing was chosen to maximize the likelihood of seeing an impact of supplementation (with doses substantially above the RDA), while staying within a range considered safe for young children. From ages 0--6 months, doses were between 150--600% of the Recommended Dietary Allowance (RDA) or Adequate Intake (AI); from 7--12 months of age, 200--400% of the RDA or AI. These doses were consistent with those used in our previous trial of multivitamin supplementation of HIV-exposed children ([@R8]). Mothers and children were followed for 18 months from the date of randomization, or until the child's death or loss to follow-up. Mothers and children returned to the study clinic every four weeks for data collection and standard clinical care. Demographic data were obtained in interviews with the mother at recruitment and monthly follow-up visits. Birth data were collected from medical records.

Iron and hematologic status {#S11}
---------------------------

Complete blood count assays were performed on venous blood draws at randomization and ages 6, 12, and 18 months using the AcT5 Diff AL hematology analyzer (Beckman Coulter, Jersey City, NJ, USA). Plasma ferritin, alpha-1-acid glycoprotein (AGP), and soluble transferrin receptor (sTfR) were measured using an enzyme-linked immunosorbent assay (ELISA; ([@R16]) in samples drawn at age 6 months and frozen at −80 °C from a subset of infants (n = 589) as part of a separate study of enteric dysfunction and growth. To be eligible for those analyses, children were required to have a blood sample available at 6 weeks and 6 months of age, and have a length-for-age Z score (LAZ) \>= −2 at 6 weeks of age.

Anemia was defined as hemoglobin concentration (Hb) \< 10.0 g/dL at baseline (six weeks of age) and \< 11.0 g/dL during follow-up, and severe anemia was defined as hemoglobin \< 8.5 g/dL at any age ([@R17]). Microcytosis was defined as mean corpuscular volume (MCV) \< 70 fL. ([@R17]) Iron deficiency was defined as ferritin \< 12 **μ**g/L or, in cases where AGP ≥ 1.0 g/L, sTfR \> 8.3 mg/L ([@R18]).

Statistical Analyses {#S12}
--------------------

Children with hemoglobin measured at baseline and at least one follow-up hemoglobin measure were included in analyses (*N* = 2006). Chi square tests were used to examine the proportion of infants with iron deficiency at age 6 months in each treatment arm. ANOVA was used to compare mean Hb, ferritin, and sTfr between treatment arms at age 6 months. Logistic regression models were used to examine treatment effects on odds of developing iron deficiency at age 6 months. Cox proportional hazard models were used to examine treatment effects on the risk of developing anemia and anemia subtypes (e.g., severe, microcytic) during follow-up. We excluded children who had anemia (remaining *n* = 1387) or severe anemia (remaining *n* = 1930) at baseline from the respective analyses conducted to determine the risk of developing anemia and anemia subtypes. ANOVA models with Bonferroni correction for post-hoc comparisons were used to compare hemoglobin among different treatment groups at baseline and ages 6, 12, and 18 months. Analyses were conducted in SAS software Version 9.1 (SAS Institute, Cary, NC, USA). Two-sided *p*-values \< 0.05 were considered statistically significant.

RESULTS {#S13}
=======

Among infants who met criteria for Hb analyses, sample characteristics were similar between treatment regimen arms ([Table 1](#T1){ref-type="table"}). Baseline characteristics were similar between infants with (*n* = 2006) and without (*n* = 394) sufficient Hb values to be included in Hb analyses and similar between infants selected for iron status assays at age 6 months (*n* = 589) and the rest of the cohort, with the exception of age at randomization. Infants with 6-month iron status values were 0.4 (95% CI 0.1 -- 0.7) days younger at enrollment than those without iron status values. Baseline demographic and birth characteristics are also shown in [Table 1](#T1){ref-type="table"}. Baseline hemoglobin values were similar between treatment arms.

[Table 2](#T2){ref-type="table"} compares iron status indicators at age 6 months among treatment arms. Infants treated with MV alone had the lowest prevalence of iron deficiency, whereas those treated with Zn alone had the highest. There were no differences among treatment arms in mean ferritin, ferritin adjusted for AGP, and sTfR. In logistic regression models, Zn treatment was associated with greater odds of iron deficiency \[OR 1.8 (95% CI 1.0 -- 3.3); *p* \< .05\], and MV treatment was associated with lower odds \[OR 0.49 (95% CI 0.3 -- 0.9); *p* \< .05\].

In Cox models, neither MV nor Zn treatment were associated with increased risk of developing anemia or microcytic anemia during the follow up period ([Table 3](#T3){ref-type="table"}). However, MV use was associated with a 28% reduction in the risk of severe anemia (HR = 0.72 \[95%CI 0.56 -- 0.94\]) and a 26% reduction in the risk of severe microcytic anemia (HR = 0.74 \[95% CI 0.56 -- 0.96\]) through age 18 mo. No effects of Zn on risk of severe anemia or severe microcytic anemia were seen. No interaction effects were seen for sex, low birthweight, preterm delivery, or baseline hemoglobin (data not shown).

Infants treated with MV alone had higher mean Hb than those given Zn alone at 12 mo (9.9 vs. 9.6 g/dL, *p* ≤ .05) and 18 mo (9.9 vs. 9.6 g/dL, *p* ≤ .05 ([Table 4](#T4){ref-type="table"})). Infants treated with MV alone had higher mean Hb than those given placebo at 18 months (9.9 vs 9.6 g/dL, *p* ≤ .05). In linear regression models including both MV and Zn treatment, MV treatment was associated with an increase in Hb of 0.2 g/dL (*p* ≤ .01) at 12 months and 0.3 g/dL (*p* ≤ .001) at 18 months. No differences in Hb values between infants treated with Zn and those with placebo or Zn + MV therapy were observed at any age.

DISCUSSION {#S14}
==========

In this trial among young infants comparing the effects of daily supplementation with zinc, multivitamin, zinc plus multivitamin, or placebo from ages 6 weeks to 18 months, Zn treatment was associated with a higher risk of iron deficiency at 6 months but no longer-term increase in risk of anemia, while MV treatment was associated with a lower risk of both iron deficiency and anemia. These findings are potentially important as zinc supplementation programs are increasingly implemented in global health initiatives.

Our finding that Zn treatment was not associated with changes in hemoglobin or risk of anemia is consistent with prior studies that have failed to show effects of zinc supplementation on hemoglobin concentrations in children ([@R10],[@R11],[@R19]). However, the odds of developing iron deficiency at age 6 months were increased by over 80% in infants treated with Zn, suggesting that Zn treatment for 18 months may worsen iron status but not to a degree severe enough to affect hemoglobin production. Anemia is a late marker of iron deficiency, as iron is preferentially shunted to hemoglobin production from tissues, including the brain, until iron deficiency becomes severe. Furthermore, iron deficiency without anemia during infancy has been associated with delays in cognitive and socioemotional development, some of which are irreversible ([@R20]--[@R23]). The importance of the age at which the effect of Zn was seen, 6 months, is underscored by the fact that most public health iron deficiency screening programs begin at age 9 or 12 months. Future studies are needed to determine whether and how the duration and/or dosage level of Zn treatment are needed before the risk of iron deficiency increases.

Previous clinical trials of iron and zinc supplementation in children have also addressed this issue. Among Mexican preschoolers, iron plus zinc increased serum ferritin less than iron alone ([@R9]). In Indonesia, the combination of both zinc (10 mg/d) and iron (10 mg/d) in infants was less effective than iron alone in reducing the occurrence of anemia ([@R8]). The effects of Zn treatment on iron status may be the result of competitive inhibition of iron absorption or utilization. Evidence suggests that zinc may compete with iron at two levels: the divalent metal transporter-1 (DMT-1) (the protein responsible for importing ferrous iron into the apical membranes of the gastrointestinal epithelial cell) and ferroportin (FPN) (the regulator of iron efflux across the basolateral membrane). Competitive inhibition of iron at these sites would thus reduce transfer of dietary iron to the bloodstream. In adult humans, zinc supplementation has been shown to reduce absorption of radio-labeled iron when the weight ratio of zinc dietary intake to iron dietary intake exceeded 5:1 ([@R6]). For infants who were mostly breastfed, this ratio may have been easily exceeded by the zinc supplementation dosage provided in this study given the relatively low iron content of breastmilk. The zinc compound used may impact potential effects on iron absorption. In a study of Indonesian school-aged children, iron absorption from flour fortified with both iron and zinc oxide was superior to flour fortified with iron and zinc sulfate, the compound used in the current study ([@R24]).

Although early iron status is largely dependent on fetal iron stores, complementary feeding was started before two months in this cohort on average (with no differences between treatment arms), making potential disruptions in intestinal iron absorption potentially more impactful. Other measured risk factors for iron deficiency, such as premature delivery and low birthweight, were similar between treatment arms. Unmeasured potential factors affecting prenatal and infant iron status include maternal iron status and lack of delayed cord clamping, but given the RCT study design, these factors were likely evenly distributed among treatment arms. Moreover, there were no group differences in baseline hemoglobin concentrations among treatment groups.

MV treatment was associated with a 26% lower risk of developing severe anemia and severe microcytic anemia during the follow up period. The fact that the magnitude of MV-associated risk reduction was similar for severe anemia, which may have many causes, and severe microcytic anemia, which is mainly caused by iron deficiency, suggests that the beneficial effects of MV treatment on hematologic status were largely due to improved iron status. In addition, MV treatment reduced the odds of developing iron deficiency at 6 months by over 50%. There are several potential mechanisms underlying the benefits of MV supplementation on iron status. Vitamin C enhances intestinal iron absorption ([@R25]). Vitamin C and E both inhibit oxidative damage of erythrocyte cell membranes ([@R26],[@R27]). B vitamins, particularly riboflavin (B-2) and B-6, play crucial roles in hemoglobin synthesis, thereby potentially decreasing anemia ([@R28]). These results extend our previous finding of improved hematologic status among infants with vertical HIV exposure treated with the same MV regimen to children without HIV exposure. Of note, both the prevalence of iron deficiency at age 6 months and hemoglobin concentrations at all ages examined were similar between infants receiving combined MV+Zn treatment and those receiving placebo. Thus, the beneficial effects of MV supplementation on iron status may counterbalance potential detrimental effects of Zn on iron status.

Several strengths of our study deserve comment. To our knowledge, our study is the first to examine the effects of zinc and multivitamin supplementation in African infants from six weeks of age and one of the first to examine hematologic and iron endpoints as early as 6 months of age. We used a 2×2 factorial double-blinded randomized control design with a large number of participants. Serial hematologic measurements at ages 6, 12, and 18 months allowed us to evaluate the effects of supplementation from age 6 months, when iron status is generally reflective of fetal iron stores, through the infancy period, when rates of iron deficiency typically increase. Our examination of iron status measures in addition to hematologic measures enabled us to detect effects on iron status even in the absence of effects on hemoglobin production. Furthermore, we examined both ferritin and soluble transferrin receptor, as well as AGP, which allowed us to detect iron deficiency even in the setting of inflammation.

Limitations of this dataset also exist. After age 6 months, our measures of iron status were limited to hematologic data, with microcytic anemia as a proxy indicator of iron deficiency. Iron deficiency is the most common cause of microcytic anemia, and while environmental lead exposure and hemoglobinopathies may also cause microcytic anemia, these factors were likely distributed evenly among treatment arms, given the randomized trial design. Given our lack of iron status measures at later ages, we were not able to examine how effects of MV and Zn treatment on iron status may have changed over time. It is unclear whether the lack of an association between MV treatment and non-severe anemia was due to a true lack of effect or inadequate power, since the number of subjects in related analyses was smaller than in the number included in analyses examining severe anemia, in which beneficial effects of MV supplementation were seen. This study did not have an iron supplementation arm, and we could thus not examine potential effects of combination therapy with iron and zinc and/or multivitamins. Due to limits on blood volumes obtained from infants, biochemical measures of infant zinc status were not available. Potential effects of maternal micronutrient deficiencies, which are common during lactation in Sub-Saharan Africa ([@R29]), were not examined in the current study, but given the RCT study design, such deficiencies were likely evenly distributed among treatment arms.

CONCLUSIONS {#S15}
===========

In this 2×2 factorial double-blind randomized control trial, treatment with multivitamins was associated with reduced risk of both iron deficiency and severe microcytic anemia, while zinc treatment was associated with increased risk of iron deficiency but no longer term increase in risk of anemia. Given the potential for neurodevelopmental sequelae of iron deficiency during infancy, even in the absence of anemia, infants in long-term zinc supplementation programs who are at risk for iron deficiency may benefit from screening and/or the addition of a multivitamin supplement, such as the one studied in this trial.
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AGP

:   α-1-acid glycoprotein

ELISA

:   enzyme-linked immunosorbent assay

MV

:   multivitamin

SGA

:   small for gestational age

sTfR

:   soluble transferrin receptor

Zn

:   zinc

###### 

Baseline characteristics of mothers and their children enrolled in the trial[a](#TFN1){ref-type="table-fn"}

  -------------------------------------------------------------------------------------------------------------------------------------------
                                                                   Placebo\     Zinc only\   Multivitamins only\   Multivitamins plus zinc\
                                                                   (n=508)      (n=494)      (n=507)               (n=497)
  ---------------------------------------------------------------- ------------ ------------ --------------------- --------------------------
  *Maternal characteristics*                                                                                       

   Age, y                                                          26.5 ± 5.0   26.9 ± 5.2   26.2 ± 5.1            26.2 ± 5.0

   Formal education                                                                                                

    None                                                           6 (1.2)      8 (1.6)      7 (1.4)               7 (1.4)

    1--7 y                                                         380 (75.1)   351 (71.3)   354 (70.5)            362 (73.0)

    ≥ 8 y                                                          120 (23.7)   133 (27.0)   141 (28.1)            127 (25.6)

   Employment                                                                                                      

    Housewife without income                                       324 (64.2)   309 (63.7)   289 (57.5)            291 (59.2)

   Housewife with income                                           148 (29.3)   141 (29.1)   178 (35.4)            170 (34.6)

   Other                                                           33 (6.5)     35 (7.2)     36 (7.2)              31 (6.3)

   Marital status                                                                                                  

    Married or cohabitating with partner                           450 (89.5)   439 (89.6)   461 (91.8)            446 (90.3)

   Prior pregnancies                                                                                               

    None                                                           151 (29.8)   137 (27.9)   176 (35.0)            153 (30.9)

    1--4                                                           336 (66.4)   343 (69.9)   317 (63.0)            328 (66.3)

    ≥ 5                                                            19 (3.8)     11 (2.2)     10 (2.0)              14 (2.8)

   Mid-upper arm circumference, cm                                 27.0 ± 3.1   27.1 ± 3.1   27.0 ± 3.1            26.7 ± 3.3

   Daily food expenditure per person in household is \< 1000 TSh   129 (26.7)   130 (27.9)   136 (28.0)            148 (31.1)

   Household possessions[b](#TFN2){ref-type="table-fn"}                                                            

    None                                                           145 (28.9)   160 (32.8)   143 (28.5)            154 (31.1)

    1--3                                                           300 (59.3)   251 (51.4)   278 (55.4)            274 (55.4)

    ≥ 3                                                            61 (12.1)    77 (15.8)    81 (16.1)             67 (13.5)

   *Child characteristics*                                                                                         

    Age at randomization, wk                                       5.9 ± 0.4    5.9 ± 0.4    5.9 ± 0.4             5.9 ± 0.4

    Male sex                                                       249 (49.0)   252 (51.0)   241 (47.5)            257 (51.7)

    Low birth weight, \<2500 g                                     13 (2.59     21 (4.3)     17 (3.4)              16 (3.3)

    Born \< 37 weeks gestational age                               59 (12.8)    72 (15.7)    54 (11.6)             57 (12.5)

    Born \< 34 weeks gestational age                               12 (2.6)     12 (2.6)     12 (2.6)              20 (4.4)

    Born small for gestational age, \<10^th^ percentile            38 (8.5)     38 (8.4)     44 (9.7)              39 (8.7)

    Any breastfeeding, mo                                          13.3 ± 5.9   13.6 ± 5.7   13.3 ± 5.8            13.0 ± 5.8

    Exclusive breastfeeding, mo                                    1.8 ± 1.5    1.9 ± 1.5    1.9 ± 1.6             1.9 ± 1.6
  -------------------------------------------------------------------------------------------------------------------------------------------

Values are means ± SD or *n* (%). There were no differences in any baseline characteristics between groups (all *p* values \> 0.05).

From a list that includes sofa, television, radio, refrigerator, and fan.

###### 

Infant iron status indicators by treatment arm at age 6 months[a](#TFN3){ref-type="table-fn"}

  -------------------------------------------------------------------------------------------------------------------------------------------------
                                                             Placebo\            Zinc\               Multivitamins\      Multivitamins plus zinc\
                                                             (N = 151)           (N = 151)           (N = 147)           (N = 144)
  ---------------------------------------------------------- ------------------- ------------------- ------------------- --------------------------
  Iron deficiency[b](#TFN4){ref-type="table-fn"} \[N (%)\]   13 (8.6)            23 (15.2)           7 (4.8)             11 (7.6)

  Ferritin, μg/L                                             48.1 (40.7, 55.4)   50.7 (43.4, 58.1)   51.3 (43.8, 58.7)   51.7 (44.1, 59.2)

   adjusted for α-1-acid glycoprotein                        47.8 (40.8, 54.9)   51.5 (43.9, 58.2)   51.3 (44.1, 58.6)   51.3 (44.1, 58.6)

  Soluble transferrin receptor, mg/L                         1.8 (1.7, 2.0)      1.8 (1.7, 2.0)      1.7 (1.5, 1.8)      1.8 (1.6, 1.9)
  -------------------------------------------------------------------------------------------------------------------------------------------------

Values are N (%) or means with 95%CI from ANOVA models.

Iron deficiency was defined as ferritin \< 12 μg/L or, where α-1-acid-glycoprotein ≥ 1.0 g/L, soluble transferrin receptor \> 8.3 mg/L.

Comparison of iron deficiency prevalence among treatment arms: *χ*2([@R3]) = 10.62, *p* = .014.

###### 

Zinc and multivitamin (MV) treatment Cox regression hazard ratios for risk of anemia outcomes in infants.

                                         Non-Zinc    Zinc                *P*    Non-MV      MV                  *P*
  -------------------------------------- ----------- ------------------- ------ ----------- ------------------- ------
                                                                                                                
  Baseline hemoglobin (Hb) ≥ 11.0 g/dL                                                                          
   N                                     718         669                        682         705                 
   Person-months                         2168.2      1983.6                     2069.4      2082.4              
   Anemia                                                                                                       
    No. of cases                         598         573                        562         609                 
    HR^a^ (95% CI)                       1.0 (N/A)   1.05 (0.93, 1.18)   0.47   1.0 (N/A)   1.09 (0.97, 1.22)   0.14
    Adjusted HR (95% CI)                 1.0 (N/A)   1.05 (0.93, 1.18)   0.43   1.0 (N/A)   1.09 (0.97, 1.23)   0.14
   Anemia + microcytosis                                                                                        
    No. of cases                         163         137                        146         154                 
    HR (95% CI)                          1.0 (N/A)   0.91 (0.72, 1.14)   0.41   1.0 (N/A)   1.07 (0.85, 1.34)   0.57
    Adjusted HR (95% CI)                 1.0 (N/A)   0.91 (0.73, 1.15)   0.43   1.0 (N/A)   1.06 (0.85, 1.33)   0.61
  Baseline hemoglobin ≥ 8.5 g/dL                                                                                
   N                                     971         959                        960         970                 
   Person-months                         8551.2      8707.2                     8581.8      8676.6              
   Severe anemia                                                                                                
    No. of cases                         119         118                        137         100                 
    HR (95% CI)                          1.0 (N/A)   1.00 (0.78, 1.30)   0.97   1.0 (N/A)   0.72 (0.56, 0.94)   0.01
    Adjusted HR (95% CI)                 1.0 (N/A)   0.99 (0.77, 1.28)   0.95   1.0 (N/A)   0.72 (0.56, 0.94)   0.01
   Severe anemia + microcytosis                                                                                 
    No. of cases                         112         109                        127         94                  
    HR (95% CI)                          1.0 (N/A)   1.05 (0.80, 1.37)   0.73   1.0 (N/A)   0.74 (0.56, 0.96)   0.02
    Adjusted HR (95% CI)                 1.0 (N/A)   1.04 (0.80, 1.36)   0.76   1.0 (N/A)   0.74 (0.56, 0.96)   0.03

HR = hazard ratio; MV = multivitamin.

###### 

Infant mean hemoglobin concentrations (g/dL) by treatment arm[a](#TFN7){ref-type="table-fn"}

             Placebo   Zinc                                             Multivitamins   Multivitamins plus Zinc                                                                                                                         
  ---------- --------- ------------------------------------------------ --------------- ----------------------------------------------- ----- ----------------------------------------------------------------------------------- ----- -------------------
                                                                                                                                                                                                                                        
  Baseline   508       10.7 (10.6, 10.9)                                497             10.6 (10.5, 10.7)                               507   10.7 (10.6, 10.8)                                                                   494   10.6 (10.5, 10.8)
  6 mo       347       10.0 (9.9, 10.1)                                 350             10.0 (9.8, 10.1)                                354   10.0 (9.9, 10.1)                                                                    352   10.0 (9.9, 10.1)
  12 mo      272       9.7 (9.5, 9.8)[b](#TFN8){ref-type="table-fn"}    273             9.6 (9.5, 9.7)[c](#TFN9){ref-type="table-fn"}   271   9.9 (9.7, 10.0)[b](#TFN8){ref-type="table-fn"}^,^[c](#TFN9){ref-type="table-fn"}    266   9.7 (9.6, 9.9)
  18 mo      168       9.6 (9.4, 9.8)[d](#TFN10){ref-type="table-fn"}   159             9.6 (9.4, 9.7)[c](#TFN9){ref-type="table-fn"}   165   9.9 (9.7, 10.1)[c](#TFN9){ref-type="table-fn"}^,^[d](#TFN10){ref-type="table-fn"}   167   9.9 (9.4, 10.0)

Values are Ns followed by mean haemoglobin (g/dL) with 95%CI from ANOVA models.

ANOVA post-hoc comparison with Bonferroni correction between multivitamin and placebo treatment *P* ≤ 0.10.

ANOVA post-hoc comparison with Bonferroni correction between multivitamin and zinc treatment *P* ≤ 0.05.

ANOVA post-hoc comparison with Bonferroni correction between multivitamin and placebo treatment *P* ≤ 0.05.
